A clinical trial to study the effects of two products Minoxidil and Parachute Advansed Therapie Hair Vitalizer for the treatment of Male Pattern Hair loss

Efficacy and Safety of Parachute Advanced Therapie Hair Vitalizer vs minoxidil in the treatment of male pattern hair loss - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/06/001826

Enrollment

Registered

2011-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Parachute Advanced Therapie Hair Vitalizer: 5 ml Topical Application at night daily for 9 months Control Intervention1: 5 % Minoxidil: Twice a day, a dose of maximum 1 ml at a single ap

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male in the age of 20 and 45 years of age. 2. Showing MPB grade of III-V on Hamilton Norwood scale. 3. Volunteers able and willing to read, understand and sign the Informed Consent form will be recruited in the study.

Exclusion criteria

Exclusion criteria: 1.Patient with scalp conditions like dandruff, dermatitis etc. 2.Patients undergoing any treatment for hair fall (includes oral and topical). 3.Patients currently on drugs which may affect hair growth (steroids, spiranolactone, minoxidil, vitamin therapy, heparin, cromakalim, cyclosporine, etc.) 4.History of intake of any Ayurvedic/herbal/homeopathic/ dietary supplements (including Vitamin E) or any alternative therapies for the last one month 5.History of any hair treatment in last 1 month. 6.Patients who are unlikely to comply with Protocol requirements e.g. uncooperative attitude, patients who are frequent travellers, inability to return for the final visit 7.Patients with known allergic hyper-sensitivity to alcohol based topical products.

Design outcomes

Primary

Measure	Time frame
Change in the Hamilton-Norwood scaleTimepoint: at 1,3, 6, 9 and 12 months	—

Secondary

Measure	Time frame
Reduction in hairfall and quality of hairTimepoint: From the baseline.	—

Countries

India

Contacts

Public ContactDr Vaishali Gode

KEM Hospital & Seth G S Medical College

drkhopkar@gmail.com02224116464

Outcome results